Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Leukemia & Lymphoma
Volume 60, 2019 - Issue 7
Lymphoma Rounds from the Lymphoma Research Foundation. Editors: Koen Van Besien and Morton Coleman
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation
Alexandra Gomez-ArteagaDepartment of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, USA; 
http://orcid.org/0000-0003-0897-3790View further author information
http://orcid.org/0000-0003-0897-3790View further author information, Elizabeth MargolskeeDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, USA; http://orcid.org/0000-0001-8597-0636View further author information
http://orcid.org/0000-0001-8597-0636View further author information, Mike T. WeiDepartment of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, USA; http://orcid.org/0000-0003-4756-9010View further author information
http://orcid.org/0000-0003-4756-9010View further author information, Koen van BesienDepartment of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, USA; Correspondence[email protected]
http://orcid.org/0000-0002-8164-6211View further author information
http://orcid.org/0000-0002-8164-6211View further author information, Giorgio InghiramiDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, USA; http://orcid.org/0000-0002-5298-6516View further author information
http://orcid.org/0000-0002-5298-6516View further author information & Steven HorwitzMemorial Sloan Kettering Cancer Center, New York, NY, USAhttp://orcid.org/0000-0002-6399-2006View further author information
http://orcid.org/0000-0002-6399-2006View further author information